Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study

Guardado en:

Detalles Bibliográficos
Autores principales:	Joseph F Merola, Frank Behrens, Marina Magrey, Liang Chen, Derek Haaland, Koji Kato, Mitsumasa Kishimoto, Patrick Zueger, Aileen L Pangan, Cesar Pacheco-Tena, John Liu, Yuanyuan Duan, Ralph Lippe
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Medicine R
Acceso en línea:	https://doaj.org/article/3246209a50e946a796e8247c73843f2e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3246209a50e946a796e8247c73843f2e
record_format	dspace
spelling	oai:doaj.org-article:3246209a50e946a796e8247c73843f2e2021-11-28T21:00:06ZUpadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study10.1136/rmdopen-2021-0018382056-5933https://doaj.org/article/3246209a50e946a796e8247c73843f2e2021-11-01T00:00:00Zhttps://rmdopen.bmj.com/content/7/3/e001838.fullhttps://doaj.org/toc/2056-5933Joseph F MerolaFrank BehrensMarina MagreyLiang ChenDerek HaalandKoji KatoMitsumasa KishimotoPatrick ZuegerAileen L PanganCesar Pacheco-TenaJohn LiuYuanyuan DuanRalph LippeBMJ Publishing GrouparticleMedicineRENRMD Open, Vol 7, Iss 3 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R
spellingShingle	Medicine R Joseph F Merola Frank Behrens Marina Magrey Liang Chen Derek Haaland Koji Kato Mitsumasa Kishimoto Patrick Zueger Aileen L Pangan Cesar Pacheco-Tena John Liu Yuanyuan Duan Ralph Lippe Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
format	article
author	Joseph F Merola Frank Behrens Marina Magrey Liang Chen Derek Haaland Koji Kato Mitsumasa Kishimoto Patrick Zueger Aileen L Pangan Cesar Pacheco-Tena John Liu Yuanyuan Duan Ralph Lippe
author_facet	Joseph F Merola Frank Behrens Marina Magrey Liang Chen Derek Haaland Koji Kato Mitsumasa Kishimoto Patrick Zueger Aileen L Pangan Cesar Pacheco-Tena John Liu Yuanyuan Duan Ralph Lippe
author_sort	Joseph F Merola
title	Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
title_short	Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
title_full	Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
title_fullStr	Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
title_full_unstemmed	Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
title_sort	upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 select-psa 1 study
publisher	BMJ Publishing Group
publishDate	2021
url	https://doaj.org/article/3246209a50e946a796e8247c73843f2e
work_keys_str_mv	AT josephfmerola upadacitinibinpatientswithpsoriaticarthritisandaninadequateresponsetononbiologicaltherapy56weekdatafromthephase3selectpsa1study AT frankbehrens upadacitinibinpatientswithpsoriaticarthritisandaninadequateresponsetononbiologicaltherapy56weekdatafromthephase3selectpsa1study AT marinamagrey upadacitinibinpatientswithpsoriaticarthritisandaninadequateresponsetononbiologicaltherapy56weekdatafromthephase3selectpsa1study AT liangchen upadacitinibinpatientswithpsoriaticarthritisandaninadequateresponsetononbiologicaltherapy56weekdatafromthephase3selectpsa1study AT derekhaaland upadacitinibinpatientswithpsoriaticarthritisandaninadequateresponsetononbiologicaltherapy56weekdatafromthephase3selectpsa1study AT kojikato upadacitinibinpatientswithpsoriaticarthritisandaninadequateresponsetononbiologicaltherapy56weekdatafromthephase3selectpsa1study AT mitsumasakishimoto upadacitinibinpatientswithpsoriaticarthritisandaninadequateresponsetononbiologicaltherapy56weekdatafromthephase3selectpsa1study AT patrickzueger upadacitinibinpatientswithpsoriaticarthritisandaninadequateresponsetononbiologicaltherapy56weekdatafromthephase3selectpsa1study AT aileenlpangan upadacitinibinpatientswithpsoriaticarthritisandaninadequateresponsetononbiologicaltherapy56weekdatafromthephase3selectpsa1study AT cesarpachecotena upadacitinibinpatientswithpsoriaticarthritisandaninadequateresponsetononbiologicaltherapy56weekdatafromthephase3selectpsa1study AT johnliu upadacitinibinpatientswithpsoriaticarthritisandaninadequateresponsetononbiologicaltherapy56weekdatafromthephase3selectpsa1study AT yuanyuanduan upadacitinibinpatientswithpsoriaticarthritisandaninadequateresponsetononbiologicaltherapy56weekdatafromthephase3selectpsa1study AT ralphlippe upadacitinibinpatientswithpsoriaticarthritisandaninadequateresponsetononbiologicaltherapy56weekdatafromthephase3selectpsa1study
_version_	1718407760613212160

Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study

Ejemplares similares